Download presentation
Presentation is loading. Please wait.
Published byAltan Çağlayan Modified over 5 years ago
1
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal Williams, MPH, Alice Catallini, BS, June Clements, MD, Shalini Singh, MD, James Amberson, MD, Kim Dickinson, MD, Zoran Gatalica, MD, Steffan N. Ho, MD, PhD, Isabell Loftin, PhD, Abigail McElhinny, PhD, Penny Towne, MBA Journal of Thoracic Oncology Volume 12, Issue 5, Pages (May 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Outcome data for discordant cases. Abbreviations: ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry. Journal of Thoracic Oncology , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
3
Figure 2 Patterns of anaplastic lymphoma kinase (ALK) immunohistochemistry (IHC) positivity in ALK IHC–positive/fluorescence in situ hybridization (FISH)–negative discordant cases. (A) ALK IHC–positive/ALK FISH-negative case displaying strong ALK IHC staining in more than 90% of tumor cells. (B) ALK IHC–positive/ALK FISH–negative case displaying heterogeneous ALK IHC staining intensity. Note diffusely distributed ALK-positive and ALK-negative tumor cells. (C) ALK IHC–positive/ALK FISH–negative case displaying heterogeneous ALK IHC staining. Note the distinct tumor areas of ALK-positive staining (right image) and ALK-negative staining (left image); areas of positivity may have been missed by FISH. Journal of Thoracic Oncology , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.